1
|
Bonfim AP, Sakita KM, Faria DR, Arita GS, Rodrigues-Vendramini FA, Capoci IR, Braga AG, Mosca VA, Junior AG, Kioshima ÉS, Bonfim-Mendonça PS, Svidzinski TI. Successful treatment of experimental murine vulvovaginal candidiasis with gentian violet. Future Microbiol 2023; 18:1137-1146. [PMID: 37830930 DOI: 10.2217/fmb-2023-0021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2023] [Accepted: 06/12/2023] [Indexed: 10/14/2023] Open
Abstract
Aim: This study evaluated the antifungal efficacy of gentian violet (GV) in an experimental vulvovaginal candidiasis (VVC) model. Materials & methods: In vitro susceptibility and cytotoxicity assays were performed to validate the antifungal potential and safety of GV. The antifungal efficacy was then evaluated in vivo through comparative analysis of the fungal burden following treatment with GV or nystatin, as well as assessment of the vaginal tissue by histology and electron microscopy. Results: GV demonstrated a safe antifungal profile against C. albicans, with a significant decrease in fungal burden and an improvement in the inflammatory process evaluated histologically. Conclusion: The results of this study motivate further assessment of GV as a promising alternative for VVC therapy.
Collapse
Affiliation(s)
- Amanda P Bonfim
- Medical Mycology Laboratory, Clinical Analyzes & Biomedicine Department, State University of Maringa, Maringa, PR, 87020-900, Brazil
| | - Karina M Sakita
- Medical Mycology Laboratory, Clinical Analyzes & Biomedicine Department, State University of Maringa, Maringa, PR, 87020-900, Brazil
| | - Daniella R Faria
- Medical Mycology Laboratory, Clinical Analyzes & Biomedicine Department, State University of Maringa, Maringa, PR, 87020-900, Brazil
| | - Glaucia S Arita
- Medical Mycology Laboratory, Clinical Analyzes & Biomedicine Department, State University of Maringa, Maringa, PR, 87020-900, Brazil
| | - Franciele Av Rodrigues-Vendramini
- Medical Mycology Laboratory, Clinical Analyzes & Biomedicine Department, State University of Maringa, Maringa, PR, 87020-900, Brazil
| | - Isis Rg Capoci
- Medical Mycology Laboratory, Clinical Analyzes & Biomedicine Department, State University of Maringa, Maringa, PR, 87020-900, Brazil
| | - Andressa G Braga
- Medical Mycology Laboratory, Clinical Analyzes & Biomedicine Department, State University of Maringa, Maringa, PR, 87020-900, Brazil
| | - Valéria Ab Mosca
- Medical Mycology Laboratory, Clinical Analyzes & Biomedicine Department, State University of Maringa, Maringa, PR, 87020-900, Brazil
| | - Admilton Go Junior
- Electron Microscopy & Microanalysis Laboratory, State University of Londrina, Londrina, PR, 86057-970, Brazil
| | - Érika S Kioshima
- Medical Mycology Laboratory, Clinical Analyzes & Biomedicine Department, State University of Maringa, Maringa, PR, 87020-900, Brazil
| | - Patrícia S Bonfim-Mendonça
- Medical Mycology Laboratory, Clinical Analyzes & Biomedicine Department, State University of Maringa, Maringa, PR, 87020-900, Brazil
| | - Terezinha Ie Svidzinski
- Medical Mycology Laboratory, Clinical Analyzes & Biomedicine Department, State University of Maringa, Maringa, PR, 87020-900, Brazil
| |
Collapse
|
2
|
Suggested Guidelines for the Treatment of Mycosis Fungoides in Countries with Limited Resources. Dermatol Res Pract 2023; 2023:1360740. [PMID: 36762366 PMCID: PMC9904957 DOI: 10.1155/2023/1360740] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2022] [Revised: 01/13/2023] [Accepted: 01/17/2023] [Indexed: 02/04/2023] Open
Abstract
The treatment options for mycosis fungoides (MF) have been expanding but unfortunately many of the currently used treatment modalities are unavailable in Egypt and other African/Arab countries. In addition, there is a lack of consensus on the treatment of hypopigmented MF (HMF), which is a frequently encountered variant in our population. We aimed to develop regional treatment guidelines based on the international guidelines but modified to encompass the restricted treatment availability and our institutional experience. Special attention was also given to studies conducted on patients with skin phototype (III-IV). Treatment algorithm was formulated at Ain-Shams cutaneous lymphoma clinic through the collaboration of dermatologists, haematologists, and oncologists. Level of evidence is specified for each treatment option. For HMF, phototherapy is recommended as a first line treatment, while low-dose methotrexate is considered a second line. For early classical MF, we recommend Psoralen-ultraviolet A (PUVA), which is a well-tolerated treatment option in dark phenotype. Addition of either retinoic acid receptor (RAR) agonist and/or methotrexate is recommended as a second line. Total skin electron beam (TSEB) is considered a third-line option. For advanced stage, PUVA plus RAR agonist and/or methotrexate is recommended as first line, TSEB or monochemotherapy is considered a second line option. Polychemotherapy is regarded as a final option. All patients with complete response (CR) enter a maintenance and follow-up schedule. We suggest a practical algorithm for the treatment of MF for patients with dark phenotype living in countries with limited resources.
Collapse
|
3
|
Das A, Toshniwal A, Madke B. What is new in dermatotherapy? Indian J Dermatol Venereol Leprol 2021; 87:135-143. [PMID: 33580938 DOI: 10.25259/ijdvl_342_20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2020] [Accepted: 07/01/2020] [Indexed: 11/04/2022]
Affiliation(s)
- Anupam Das
- Department of Dermatology, KPC Medical College and Hospital, Kolkata, West Bengal, India
| | - Anand Toshniwal
- Aesthetic Aura Skin and Hair Clinic, Hyderabad, Telangana, India
| | - Bhushan Madke
- Department of Dermatology, Jawaharlal Nehru Medical College and AVBR Hospital, Wardha, Maharashtra, India
| |
Collapse
|
4
|
Mirza FN, Yumeen S, Lewis JM, King ALO, Kim SR, Carlson KR, Umlauf S, Surovtseva YV, Foss FM, Girardi M. Screening Novel Agent Combinations to Expedite CTCL Therapeutic Development. J Invest Dermatol 2021; 141:217-221. [DOI: 10.1016/j.jid.2020.05.097] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2020] [Revised: 05/04/2020] [Accepted: 05/05/2020] [Indexed: 01/22/2023]
|
5
|
Westergaard SA, Lechowicz MJ, Harrington M, Elsey J, Arbiser JL, Khan MK. Induction of remission in a patient with end-stage cutaneous T-cell lymphoma by concurrent use of radiation therapy, gentian violet, and mogamulizumab. JAAD Case Rep 2020; 6:761-765. [PMID: 32728607 PMCID: PMC7381503 DOI: 10.1016/j.jdcr.2020.05.035] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Affiliation(s)
- Sarah A Westergaard
- Department of Radiation Therapy, Emory University School of Medicine, Atlanta, Georgia
| | - Mary Jo Lechowicz
- Department of Hematology/Oncology, Emory University School of Medicine, Atlanta, Georgia
| | - Maggie Harrington
- Department of Hematology/Oncology, Emory University School of Medicine, Atlanta, Georgia
| | - Justin Elsey
- Department of Dermatology, Emory University School of Medicine, Atlanta, Georgia
| | - Jack L Arbiser
- Department of Dermatology, Emory University School of Medicine, Atlanta, Georgia.,Veterans Affairs Medical Center, Decatur, Georgia
| | - Mohammad K Khan
- Department of Radiation Therapy, Emory University School of Medicine, Atlanta, Georgia
| |
Collapse
|